UK cell and gene therapy capacity hike signals long-term role says CGT

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Gene therapy, United kingdom, Uk

Recent capacity growth means the UK will be a cell and gene therapy hub for years to come according to the authors of a new manufacturing survey. 

The Cell and Gene Therapy Catapult (CGT) made the prediction this week, citing the three gene therapy facilities and one cell therapy plant built in the UK since 2013 as an indication of an emerging long-term trend.

COO Stephen Ward told us “the increase in capacity is a positive trend that reflects the support provided by the UK Government​” citing the biomanufacturing facility recently opened by Oxford Biomedica as an example.

The facility will supply Novartis with viral vectors for its candidate products​” he said, adding that “because it is hard to move production once it has begun, the site is also likely to play a role in commercial production.”

Annual survey

CGT has examined UK manufacturing capacity annually since 2013 following a recommendation by the UK government House of Lords 2013-14 Regenerative Medicine report. 

The CGT research also showed that the UK’s clean room footprint increased 9% and the number of people employed by cell and gene therapy manufacturers grew 20% - from 324 to 391 – between 2014 and 2015. 

In addition, while Cambridge is still the hub of cell and gene therapy production, the authors also highlighted the fact the new capacity has been set up in London, Glasgow, Oxford and Birmingham in 2016 as positive sign of growth.

Tech and capacity

CGT is an Innovate UK funded organisation tasked with fostering UK cell and gene production. 

Part of this is through the development of technologies. In January​ for example it partnered with Synpromics to develop a low cost means of making viral vectors for gene therapy delivery  

Another of CGT’s roles is to provide firms with space to develop cell and gene therapy production processes​. The organisation is building a large-scale production facility in Stevenage​ to support commercial production.

Related news

Show more

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Related suppliers

Follow us


View more